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O2/air mixtures
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Background: Earlier software versions of the Zeus® (Lübeck, Dräger, Germany) failed to provide true closed circuit
anesthesia (CCA) conditions. We examined whether the latest software (SW 4.03 MK 04672–00) achieves this goal.
Methods: In 8 ASA I–III patients, the CCA mode of the Zeus® was used to maintain the inspired O2 (FIO2) and
end-expired sevoflurane % (FAsevo) at 50 and 1.8%, respectively. The fresh gas flow (FGF) of O2 and air and the
sevoflurane injection rate (=Vinjsevo, mL liquid sevo/h) were videotaped from the control screen and entered
offline into a spreadsheet. Cumulative sevoflurane usage during early wash-in (=0-1 min, CDsevo0-1), late wash-in
(=1-5 min, CDsevo1-5), and maintenance (=5-60 min, CDsevo5-60) was calculated, and Vinjsevo between 1 and 60 min
was compared with published uptake data.
Results: FAsevo reached 1.8% within 101 (23) sec. CDsevo0-1 was between 1.24 (0.03) and 3.01(0.25) mL (a range is
provided because no absolute Vinjsevo values were displayed once Vinjsevo was > 100 mL/h, which occurred
between 15 ± 2 and 46 ± 6 sec). CDsevo1-5 was 0.81 (0.37) mL, and CDsevo5-60 was 4.63 (0.94) mL. The Vinjsevo
pattern between 1 and 60 min matched previously published uptake data. Brief high FGF periods were used to
maintain the target FIO2, and to refill the reservoir bag after external pressure had been applied to the abdomen;
subsequent “spikes” wasted 0.08-0.19 mL and 0.14-0.49 mL sevoflurane (1-3% and 3-9% of total agent usage between 1
and 60 min, respectively).
Conclusion: Under the conditions specified, the Zeus® approaches CCA conditions so closely that further reductions in
agent usage would have minimal economic significance.
Keywords: Inhaled anesthetics, Equipment, Closed circuit anesthesiaBackground
Closed-circuit anesthesia (CCA) conditions exist when
the amount of agent and carrier gas administered match
the amounts needed to prime the circle breathing system,
taken up by the patient, and lost via leaks. The initial ver-
sion of the only commercially available automated closed
circuit anesthesia (CCA) machine at the time of the study,
the Zeus® (Lübeck, Dräger, Germany), failed to reduce
agent usage to levels approaching CCA conditions,
because FGF usage during the first minutes had been
programmed excessively high [1,2]. New software now
limits the duration and the pattern of the initial high* Correspondence: jcnwahendrickx@yahoo.com
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article, unless otherwise stated.FGF period and has limited the number of intermittent
high FGF flushes during maintenance (intended to re-
duce unwanted gases like N2, compound A, carbon
monoxide, methane). We hypothesize this should im-
prove the performance by reducing agent and carrier
gas usage to near closed-circuit conditions, and there-
fore studied the sevoflurane usage with the latest soft-
ware version, SW 4.03 MK 04672–00, in the automated
CCA mode.Methods
After obtaining IRB approval (IRB of the Kliniek Sint
Jan, Brussels, Belgium; Human studies number OM072
Ref 2012.115) and written informed consent, 8 ASA I –
III patients presenting for abdominal or breast surgeryntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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recorded. One hour prior to surgery, 0.5 mg alprazolam
p.o. was administered. After preoxygenation with 8 L/min
O2 by facemask, anesthesia was induced with sufentanil
(0.1 mg/kg) and propofol (3 mg/kg). Intubation of the tra-
chea was facilitated by rocuronium (0.5 mg/kg) or cisatra-
curium (0.1-0.15 mg/kg).
After connecting the endotracheal tube to the anesthesia
circuit, ventilation was mechanically controlled with the
Zeus® anesthesia machine (software version SW 4.03 MK
04672–00), with tidal volume = 500 mL, respiratory rate =
10/min, and I:E ratio = 1:2. The attending anesthesiologist
was allowed to adjust ventilation to maintain normocap-
nia. Anesthesia was maintained with sevoflurane in O2/air
using the automated CCA mode. Time zero was the time
at which the target FIO2 was set at 50% and the target
end-expired sevoflurane concentration (FAsevo) at 1.8%.
From this point on, the machine automatically ad-
justed the O2 and air FGF as well as the sevoflurane
liquid injection rate (Vinjsevo) to attain and maintain
the specified targets. Additional sufentanil and rocuro-
nium or cisatracurium administration were left at the
discretion of the attending anesthesiologist. The study
arbitrarily lasted 60 min.
Because we could not obtain software to download the
data with a resolution sufficient for the purposes of this
study (at least every second), the monitor screen was
video-recorded. The values of the following parameters
were entered offline every second into a spreadsheet
(amounting to 3600 entries per parameter per patient):
(1) time; (2) the O2 and air FGF and Vinjsevo; and (3) the
resulting inspired and end-expired O2, CO2, and sevo-
flurane concentrations (FIO2, FAO2, FICO2, FACO2,
FIsevo, and FAsevo, respectively).
Cumulative sevoflurane consumption was obtained
by integrating the area under the curve of Vinjsevo. The
Vinjsevo value is displayed on the Zeus screen. This
value is the average of multiple, very precisely dosed li-
quid “pulses” injected per second from the so-called
DIVA cassette, basically a fuel-injector from a car en-
gine that injects liquid agent with precise dosing vol-
ume of 3 to 50 microL (Wilfried Buschke, Dräger,
personal communication).
To assess how closed the Zeus® worked, we compared
the Vinjsevo pattern with previously published sevoflur-
ane uptake data derived from several different sources:
closed circuit liquid injection [3,4], indirect calorimetry
(gas balances within the circuit) [5,6], and the reverse
Fick method [5,6]. A proportional correction was applied
to account for differences in FAsevo. Patient demograph-
ics, cumulative agent usage, and times are presented as
mean ± standard deviation. Because other data (FGF,
Vinjsevo, FAsevo) are not normally distributed, they are
presented as median and quartiles.Results
Patient age, height, and weight were 58 ± 13 years, 164 ±
9 cm, and 77 ± 15 kg. Median total FGF (Figure 1a)
remained between 150 and 200 mL/min throughout the
procedure, with the composition changing progressively
from air to O2 (Figure 1b,c) as the FIO2 decreased slowly
towards the target 50% (Figure 1d). High FGF bursts were
few (Table 1), and were mainly used to increase FIO2 to its
target or to fill the breathing bag after pressure had been
exerted on the abdomen or thorax by the surgical team
that resulted in loss of gas from the system.
FAsevo reached 1.8% within 101 ± 23 sec (Figure 2a)
and was maintained within 0.1% thereafter (Figure 2b).
After the first minute, the Vinjsevo pattern matched pre-
viously published uptake data [3-6] (Figure 2c). Vinjsevo
“spikes” followed the high FGF episodes mentioned
above, and wasted 0.08-0.19 mL and 0.14-0.49 mL liquid
sevoflurane when used to increase FIO2 and after external
pressure had been applied to the abdomen, constituting 1-
3% and 3-9% of total agent usage between 1 and 60 min,
respectively (Table 1).
Cumulative liquid sevoflurane usage was 0.81 ± 0.37 mL
between 1–5 min, and 4.63 ± 0.94 mL between 5–60 min.
The cumulative sevoflurane usage between 0 and 1 min
could not be accurately measured because Vinjsevo
was > 100 mL/h between 15 ± 2 and 46 ± 6 sec (Figure 2d);
under these circumstances, the Zeus ceases to display
values and only displays a message “Vinjsevo > 100 mL/h”.
Still, cumulative agent usage can be reported as a
range because the maximum Vinjsevo = 300 mL/h, thus
the injection rate during these “blackout” episodes
has to lie between 100 and 300 mL/h. For example,
for a 12 sec blackout period, the cumulative sevoflurane
amount ranges between 0.33 to 1 mL liquid. Accord-
ing to these injector limits, cumulative sevoflurane
usage between 0 and 1 min was between 1.24 ± 0.03 and
3.01 ± 0.25 mL.
Discussion
While older studies found that with the older algorithms
the Zeus® could not reduce agent usage to the amounts
needed to prime the system and to replace the amounts
taken up by the patient [2], our current data suggest that
the newest algorithms applied by the Zeus® have suc-
ceeded in reducing agent usage to just 4–12% above CCA
conditions [3-5]. Besides software improvements, other
factors may account for this.
First, the algorithms steering the FGF and agent in-
jector during wash-in have been optimized. The Zeus®
manages FGF and agent administration to attain and
maintain the initial target FA of the agent and carrier gases
in such a manner that an acceptable trade-off is made be-
tween the speed of reaching the targets (FAO2, FAN2O,

























































































Figure 1 Carrier gas characteristics. Total fresh gas flow remained below 200 mL/min (a), but the composition of the fresh gas changed over
time: air fresh gas flow (b) decreased, while O2 fresh gas flow (c) increased. The inspired O2 concentration progressively decreased towards the
target of 50% (d). Thick lines = median, thin lines = quartiles.
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priority, necessitating a rapid “step” change and thus a
high FGF, which comes at the price of increased agent
usage. The response to a request for a lower FIO2 may be
allowed more time. Exceptions may include the use of
laser in the airway, or the care of neonates where a fast re-
duction in FIO2 may be required. This can be accom-
plished by the use of a fast flush button pre-programmed
with a FGF according to the user’s preference, but the
usage of any concomitantly administered agent will in-
crease. A request for a higher FA agent does not require a
high FGF because agent administration and FGF are
mechanically uncoupled: agent is injected by the DIVA
cassette, and a blower ensures rapid mixing in the circuit.
The high FGFs programmed into the early software dur-
ing initial wash-in have been rewritten: FIO2 is allowed to
drift gradually towards the target FIO2 if the initial FIO2 is
higher than the target FIO2. Figure 1 illustrates that the
average total FGF during the first 5 min varies within a
small marge of 150–210 mL/min.
Second, N2O used in previous studies may have in-
creased agent usage compared to N2 (used in this study).
If N2O is used, high initial FGF are required to achievesufficiently high concentrations of N2O in a fairly short
time period. Therefore, it is more difficult to maintain
CCA from the very beginning of the anesthetic, and
agent usage will initially be higher compared to when
O2/N2 is used. However, (1) FAN2O may be allowed to
rise more gradually, and (2) the effect of N2O on agent
consumption is bimodal: after a while, total agent usage
doses become lower when N2O is used because a lower
agent concentration can be used [7].
Third, few high FGF bursts (flushing) were used during
the maintenance phase (Table 1). What purpose do these
high FGF bursts serve, to what extent do they increase
agent usage, why were they infrequent in our study, and
can they be further reduced or eliminated all together?
Earlier software versions commanded “routine” inter-
mittent flushing of the breathing system to eliminate
unwanted gases like CO, compound A, or methane.
However, their clinical relevance has become question-
able (with KOH free CO2 absorbents) or entirely irrele-
vant (with KOH and NaOH free CO2 absorbents).
These “routine” bursts have therefore been eliminated,
but the concerned anesthesiologist can activate the flush
button.
Table 1 Overview of intermittent high fresh gas episodes and ensuing sevoflurane spikes
High FGF episodes Sevoflurane spikes










min L/min % O2 sec L mL/h mL/h sec mL #
FAsevo overshoot + Autoflush 2 6.4 21 36 3.86 part of washin after overshoot, N/A 1
CO2 sampling issue Autoflush 7 2.1 100 31 1.10 followed by sampling issue N/A 1
During calibration Calibration 27 2.0 33 19 0.65 no change N/A 2
Pressure on abdomen Bag filling 14 14.0 38 7 1.64 7 84-198 7 0.15-0.39* 3-7 5
Bag filling 20 13.8 100 7 1.61 8 79-165 7 0.14-0.32 * 3-6 4
Bag filling 25 13.3 99 6 1.33 6 58-131 11 0.16-0.40* 3-7 5
Bag filling 25 13.2 21 6 1.32 4 72-172 8 0.15-0.38* 3-7 2
Bag filling 33 16.6 100 6 1.66 4 89 6 0.14 3 3
Bag filling 34 16.9 98 6 1.69 4 100-300 6 0.16-0.49* 3-9 3
FIO2 < 50% Autoflush 45 1.9 100 27 0.87 5 6 209 0.08 2 6
Autoflush 51 2.3 100 26 0.98 7 21 20 0.08 1 4
Autoflush 52 1.9 100 33 1.07 5 7 311 0.19 3 7
Autoflush 55 1.7 100 37 1.04 2 4 254 0.16 3 1
Pressure on abdomen + FIO2 < 50% Bag filling, then autoflush 36 3.1 60 32 1.68 4 13 60 0.15 3 3
FAsevo = end-expired sevoflurane %; FGF = fresh gas flow; Av = average; Vsevo = sevoflurane usage; Pt = patient; N/A = not applicable.













































































































































Figure 2 Inspired and end-expired sevoflurane concentrations during wash-in (a) and maintenance (b) (upper and lower line, thick
line =mean, thin lines = standard deviation), and corresponding liquid sevoflurane injection rate (mL/h) (c and d, respectively). During
the first 5 minutes (c), the liquid sevoflurane injection rate (mL/h) could not be accurately measured between 15 ± 2 and 46 ± 6 sec because
Vinjsevo was > 100 mL/h (see text for details). The sevoflurane injection rates match those of previously published sevoflurane uptake data derived
from several different sources (d): closed circuit liquid injection (yellow line = Lockwood data, green line = Hendrickx data) [3,4], indirect calorimetry
(gas balances within the circuit = red line) [5,6], and the reverse Fick method (pink line) [5,6]. Thick lines =median, thin lines = quartiles.
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has been exceeded when N2O/O2 is used, or more pre-
cisely after the 10% “balance gas” threshold has been
exceeded (N2 continues to be released from slowly
equilibrating tissues and thus slowly accumulates in the
circuit). The balance gas is calculated as follows: 100% -
(FIN2O + FIO2 + FAagent + 7 vol% H2O). Because we
used O2/air as the carrier gas, and because the FIO2 was
allowed to gradually drift down towards the target FIO2,
very few high FGF bursts were needed (n = 5, total
wasted carrier gas volume 1.1 ± 0.3 L) (Table 1). But
even with the use of O2/air mixtures, the continued re-
lease of N2 may cause the FIO2 to eventually drop below
its target, initiating a brief O2 flush, which occurred in 4
patients after 45 min (Table 1).
Six FGF bursts were also prompted by a decrease of
the pressure in the breathing bag at end-expiration
caused by pressure exerted on the abdomen or thorax
by the surgical team; these were short-lived (6.3 ±
0.5 sec) and wasted 1.5 ± 0.2 L of circuit gas. The bag is
part of the FGF uncoupling system; if the pressure in the
bag is not slightly positive at the end of expiration, thesystem perceives this as lack of sufficient fresh gas, and
the FGF is increased. Three other bursts occurred after
gas sampling line kinking (for safety reasons no rebreath-
ing is allowed without 2 properly functioning gas ana-
lyzers), FAsevo overshoot (a maximum increase of 15%
above target is allowed), or post-calibration (even though
this did not happen after other calibration periods).
FGF bursts are also used to rapidly attain new targets
during the maintenance phase. Demand for a higher
FIO2 or lower FA agent in particular are considered high
priority requests, necessitating a rapid “step” change and
thus a high FGF period, which does come at the price of
increased agent usage. The response to a demand for a
lower FIO2 is allowed more time (see above). A demand
for a higher FA agent does not require a high FGF be-
cause agent administration does not depend on FGF (it
is injected by the DIVA cassette, and a blower ensures
rapid mixing in the circuit). Because we did not change
the O2 and FAsevo targets, the number of FGF bursts
and thus carrier gas and agent waste were minimized.
We believe our results allow us to conclude that the
Zeus decreases agent usage to very-near CCA conditions.
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flurane usage is unkown, but from the injector limits we
can deduct it is between 1.24 ± 0.03 and 3.01 ± 0.25 mL.
Future studies might consider weighing the DIVA cassette
or determine the amount of agent exhausted towards the
scavenging system. Our preliminary data indicate that
sevoflurane waste from the exhaust valve under identical
study conditions is 0.014 ± 0.004 mL (range 0 – 0.018 mL)
liquid sevoflurane during the first 5 min. The first few mi-
nutes of agent delivery are crucial to help minimize agent
waste. Comparison of usage data of the first few minutes
between studies is complicated by differences in circle sys-
tem configurations and the rate of rise of the agent con-
centration. During maintenance, the current software
version of the Zeus® reduces total FGF and O2 FGF in par-
ticular to previously published uptake rates [8]. But the
number of these high FGF episodes and their effect on
concomitant agent usage has become so small that the ex-
cess waste has become negligible vis-à-vis total sevoflur-
ane usage - further reductions would be economically and
environmentally insignificant, and technically difficult to
achieve.
There are several implications of our findings. First,
technology has evolved up to a point where potent in-
haled anesthetic agents can be administered with almost
no waste. Still, the “purist” can keep agent usage low by
minimizing target changes and by accepting that targets
be reached gradually [9], principles that apply to any
CCA technique. Second, considering that most anesthe-
siologists still use a maintenance FGF of 1.5 – 2 L/min
when using a conventional anesthesia machine [10,11],
automating CCA to maintain FAsevo at 1.8% in O2/air
will reduce agent usage during the maintenance phase (0
– 55 min) alone by 367%, from 17.0 mL [12] to 4.63 mL
(current study). Yet how this will translate into costs
savings is complex, and requires considerable detailed
information. For example, one study that compared the
costs of the Zeus with the Primus failed to accurately
compare the FA agent and the number of FA agent
changes, the initial FGFs, and the O2 concentrations,
precluding any meaningful conclusions to be made from
these results [13]. Another example is the imposed use
of high FGF when sevoflurane is used due to concerns
for Compound A or CO formation: although the newer
CO2 absorbents do not produce these substances, the in-
creased cost of the more expensive and less efficient
KOH and NaOH free CO2 absorbent will still be out-
weighed by the savings made by using less sevoflurane
when using an automated CCA machine [14]. Finally,
the inhaled anesthetic drugs released during the approxi-
mately 200 million anesthetic procedures performed
each year globally have a climate impact that is approxi-
mately 0.01% of that of the CO2 released from global
fossil fuel combustion [15]. Technology now enables usto even reduce this by another order of magnitude,
making our contribution to ozone layer destruction and
green house effect exceedingly small.
Conclusions
Under the conditions specified in this study, software
version SW 4.03 MK 04672–00 has made the automated
CCA mode of the Zeus® approach CCA conditions ex-
cept for brief functional high FGF episodes that result in
waste of 3-9% per episode of the total amount of agent
administered. Strictly speaking, CCA conditions still
were not met 100% of the time, but even under the best
of conditions, there always will be some need for inter-
mittent high FGF bursts. It is unlikely this very small
amount of waste can be further reduced, and it is likely
that any further reduction would be irrelevant. We con-
clude that the Zeus approaches CCA conditions.
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